MAIA Biotechnology, a Phase 2 biotech developing targeted immunotherapies for cancer, filed on Monday with the SEC to raise up to $15 million in an initial public offering.
The company’s lead candidate, THIO, is expected to enter Phase 2 human trials in Australia and Europe in the 1H22 for Non-Small Cell Lung Cancer (NSCLC). Based on the clinical data generated by the THIO-101 trial, MAIA Biotechnology plans to seek an accelerated approval of THIO in the US for treatment of advanced NSCLC in late 2024. In addition, the company intends to start planning a trial of THIO for advanced colorectal cancer in the 1Q23.
The Chicago, IL-based company was founded in 2018 and plans to list on the Nasdaq under the symbol MAIA. MAIA Biotechnology filed confidentially on October 15, 2021. ThinkEquity is the sole bookrunner on the deal. No pricing terms were disclosed.
The Chicago, IL-based organization was established in 2018 and plans to list on the Nasdaq under the image MAIA. MAIA Biotechnology recorded secretly on October 15, 2021. ThinkEquity is the sole bookrunner on the arrangement. No it were revealed to cost terms.
The organization's lead up-and-comer, THIO, is supposed to enter Phase 2 human preliminaries in Australia and Europe in the 1H22 for Non-Small Cell Lung Cancer (NSCLC). In light of the clinical information produced by the THIO-101 preliminary, MAIA Biotechnology intends to look for a sped up endorsement of THIO in the US for treatment of cutting edge NSCLC in late 2024. Moreover, the organization expects to begin arranging a preliminary of THIO for cutting edge colorectal disease in the 1Q23.